---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-106345"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2024-09-13T23:59:59+00:00"
generated_at: "2026-05-31T05:00:00.359357+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics receives Nasdaq MVLS deficiency notice; has until March 12, 2025 to comply

## Summary
- Received Nasdaq letter on September 13, 2024 for failing MVLS (minimum value of listed securities) requirement.
- MVLS was below $35 million for 30 consecutive trading days, violating Nasdaq Listing Rule 5550(b)(2).
- Company has 180 calendar days, until March 12, 2025, to regain compliance.
- To comply, MVLS must be $35M or more for at least 10 consecutive trading days.
- Failure to cure may lead to delisting; company may then appeal to a Hearings Panel.

## SEC filing metadata
- accession: 0000950170-24-106345
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2024-09-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000095017024106345/0000950170-24-106345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000095017024106345/inkt-20240913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-106345
- JSON: https://secwatch.observer/filing/0000950170-24-106345.json
- Plain text: https://secwatch.observer/filing/0000950170-24-106345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.